Literature DB >> 19821416

Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease.

Louisa Ng1, Fary Khan, Susan Mathers.   

Abstract

BACKGROUND: Multidisciplinary care (MDC) is increasingly thought to be an important means of symptomatic and supportive management for motor neuron disease (MND) but the evidence base for its effectiveness is unclear.
OBJECTIVES: To assess the effectiveness of MDC in adults with MND, especially the types of approaches that are effective (settings, intensity) and the outcomes that are affected. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Disease Group Specialized Register (11 May 2009), and The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2009), MEDLINE (1966 to April 2009), EMBASE (1980 to April 2009), CINAHLPlus (1937 to April 2009), AMED (1985 to April 2009) and LILACS (1982 to April 2009). SELECTION CRITERIA: Randomised and controlled clinical trials that compared MDC in MND with either routinely available local services or lower levels of intervention; or studies that compared MDC in different settings or at different levels of intensity.Studies of 'other designs' (such as observational studies) were included only in the Discussion since such studies could only be of limited contribution to the best evidence synthesis. DATA COLLECTION AND ANALYSIS: We performed a 'best evidence' synthesis based on methodological quality. We grouped studies in terms of setting and intensity (high or low) of therapy. MAIN
RESULTS: No randomised controlled trials or controlled clinical trials were identified. We summarised the results of five observational studies (including one with two reports) in the Discussion section of this review. AUTHORS'
CONCLUSIONS: In the absence of randomised controlled trials or controlled clinical trials, the 'best' evidence to date is based on three 'low' and two 'very low quality' observational studies. These suggest 'very low quality evidence' for an advantage for mental health domains (only) of quality of life without increasing healthcare costs, and 'low level quality' evidence for reduced hospitalisation for MDC in low-intensity outpatient settings; and 'very low quality' evidence for improved disability in high-intensity settings. The evidence for survival is conflicting. These conclusions are tentative and the gap in current research should not be interpreted as proof that MDC is ineffective. Further research is needed into appropriate study designs; outcome measurement; caregiver needs; and the evaluation of optimal settings, type, intensity or frequency and cost-effectiveness of MDC in the MND population. Future research should focus on observational designs to assess care and outcomes in 'real-life' settings. The interface between neurology, rehabilitation and palliative care should be explored to provide long-term support for MND.

Entities:  

Mesh:

Year:  2009        PMID: 19821416     DOI: 10.1002/14651858.CD007425.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  22 in total

1.  [Provision of assistive devices in amyotrophic lateral sclerosis. Analysis of 3 years case management in an internet-based supply network].

Authors:  A Funke; T Grehl; J Großkreutz; C Münch; B Walter; D Kettemann; C Karnapp; N Gajewski; R Meyer; A Maier; K M Gruhn; T Prell; K Kollewe; S Abdulla; X Kobeleva; S Körner; S Petri; T Meyer
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 2.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

3.  Factors predicting survival in ALS: a multicenter Italian study.

Authors:  Andrea Calvo; Cristina Moglia; Christian Lunetta; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialo; Gianni Sorarù; Francesca Trojsi; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Adriano Chiò; Valeria Ada Sansone; Gabriele Mora; Vincenzo Silani; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Maria Rosaria Monsurrò; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Nicola Fini; Jessica Mandrioli
Journal:  J Neurol       Date:  2016-10-24       Impact factor: 4.849

4.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.

Authors:  Alok K Sharma; Hemangi M Sane; Amruta A Paranjape; Nandini Gokulchandran; Anjana Nagrajan; Myola D'sa; Prerna B Badhe
Journal:  Am J Stem Cells       Date:  2015-03-15

Review 5.  The impact of rehabilitative interventions on quality of life: a qualitative evidence synthesis of personal experiences of individuals with amyotrophic lateral sclerosis.

Authors:  Ammarah Y Soofi; Vanina Dal Bello-Haas; Michelle E Kho; Lori Letts
Journal:  Qual Life Res       Date:  2017-12-04       Impact factor: 4.147

Review 6.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

7.  How Narrative Journalistic Stories Can Communicate the Individual's Challenges of Daily Living with Amyotrophic Lateral Sclerosis.

Authors:  Jørgen Jeppesen; Jes Rahbek; Ole Gredal; Helle Ploug Hansen
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

Review 8.  WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.

Authors:  Cathy Payne; Philip J Wiffen; Suzanne Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-04-07

9.  Shifting Tides Toward a Proactive Patient-Centered Approach in Dysphagia Management of Neurodegenerative Disease.

Authors:  Nicole M Rogus-Pulia; Emily K Plowman
Journal:  Am J Speech Lang Pathol       Date:  2020-07-10       Impact factor: 2.408

10.  Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care.

Authors:  Anne Hogden; David Greenfield; Peter Nugus; Matthew C Kiernan
Journal:  Health Expect       Date:  2013-12-23       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.